Join the club for FREE to access the whole archive and other member benefits.

EA-2353, a photoreceptor regeneration treatment for blindness, by Endogena Therapeutics


Key points from article :

Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353.

EA-2353 is a photoreceptor regeneration treatment for retinitis pigmentosa (RP).

RP is a leading cause of inherited blindness, with an estimated 1.5 million people worldwide presently affected.

EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells.

Principal investigator, Mark Pennesi, said: “This ... new treatment has the potential to be a major game-changer for patients with RP who currently have no other options.”

Endogena’s artificial intelligence-driven drug discovery platform, combined with molecular pathways that regulate retinal stem cells and retinal pigment epithelial cells, provides a potential new treatment to tackle degenerative conditions related to aging and genetic disorders. 

Endogena's gene-independent treatment has shown advantages in retinitis pigmentosa

Mentioned in this article:

Click on resource name for more details.

Endogena Therapeutics

Clinical-stage biotech company focussed on endogenous regenerative medicines

Mark Pennesi

Professor of Ophthalmology at the Casey Eye Institute Oregon Health & Science University (OHSU) in Oregon